Supply is finally fixed and a direct US commercial option is on the table—but the biosimilar maker still needs a record fourth quarter to make the math work.
ALVO · Earnings Call · 2026-11-12
The quarter that was supposed to be the turn
For two years, Alvotech’s story has been a manufacturing remediation story dressed up as a biosimilar growth story. Q3 2026 shows the remediation is finally producing operating leverage, but not yet financial proof. Nine-month revenue was $323 million, down 23% year over year, while adjusted EBITDA rose 15% to $78 million. Q3 alone: total revenue of $112 million, up 5% sequentially but down 2% year over year; product revenue of $58 million, up 78% year over year; gross margin of 54%, up 3 percentage points sequentially. The product line is healing. The licensing line remains lumpy.
What actually changed in the quarter is in Iceland. The FDA closed its May inspection with a voluntary action indicated classification, then approved additional Simlandi drug substance capacity in DSM1 and DSM2 and approved Process 2.0. Joe McClellan: “Process 2.0 more than doubles drug substance output per batch compared with the previously approved process.” — Joseph E. McClellan, Likely Executive or Senior Management (e.g., Head of Manufacturing or Operations) · 2026-11-12 That is a step change in manufacturing process economics. It also doubles available US drug substance capacity and frees scheduling. For a company whose constraint has been supply, not demand, that is the first genuine de-bottlenecking in several quarters. It also supports the new launch cadence management keeps promising.
But the financial guidance still depends on a quarter that has not happened yet. Linda Jonsdottir: “we are confident in the lower end of the current range that we issued yesterday.” — Linda Jonsdottir, Likely CFO or Head of Finance · 2026-11-12 The full-year range is $650-700 million revenue and $180-220 million EBITDA. At the low end, Q4 must produce roughly $327 million of revenue and $102 million of EBITDA—more than the entire first nine months combined on both lines. Robert Wessman did not hedge the shape:
We expect the fourth quarter to be the strongest in Alvotech history and we have a strong order book as we move into the year 2027.
That is the whole investment case in one sentence. Either Q4 is a step-function quarter or the year misses.
From partner-only to selective principal
The more interesting strategic change is the Lotus Pharmaceutical agreement for AVT34 and AVT87, proposed biosimilars to Imfinzi and Hemlibra. The economics include up to approximately $150 million in potential upfront and milestone payments plus future supply revenue. More important, it gives Alvotech a direct US commercial role for the first time, alongside Lotus and Alvogen, while retaining the right to commercialize directly. Lisa Graver: “for the first time, Alvotech will have the opportunity to participate directly in the commercialization of its products in The US.” — Lisa Graver, Likely Executive or Senior Management (e.g., Head of Commercial or similar) · 2026-11-12
That is a real evolution of the strategic partnership model. Alvotech has historically been a B2B supplier—develop, manufacture, hand off to partners, collect milestones and supply revenue. Lotus does not abandon that model, but it creates a template for capturing more value where the economics justify it. It is option value, not near-term revenue, and management was careful not to oversell the timing. The supply side is moving in the same direction: Lotte Biologics will make drug substance at its Syracuse, New York facility, and Fujifilm is expected to begin commercial production in the second half of 2027. Those deals add drug substance redundancy and a US manufacturing footprint, which matters for both resilience and political risk.
The pipeline is ahead; the litigation is binary
The pipeline is where Alvotech genuinely looks ahead of the field. AVT16 and AVT80, the intravenous and subcutaneous Entyvio biosimilars, are under review in both the US and Europe; management says it was first to file in both regions. AVT29, the high-dose Eylea biosimilar, became the first known regulatory submission worldwide for that molecule when it was filed in Europe as a line extension; the application has been validated, and the US clinical study remains on track. This is not sector boilerplate: high dose aflibercept is a large, fast-shifting market, and being early matters if the reference product converts quickly.
The catch is that the near-term US launches are legal events as much as regulatory ones. AVT05, the Simponi biosimilar, has a preliminary injunction motion pending in the Eastern District of Virginia; a hearing has been held and a ruling is expected in the coming weeks. Graver: “we remain confident in our position. And that the motion will be denied.” — Lisa Graver, Likely Executive or Senior Management (e.g., Head of Commercial or similar) · 2026-11-12 On Entyvio, the asserted patents are method-of-treatment and dosing-regimen patents, and management points to strong invalidity positions. Investors have heard this confidence before. What is new is the compression of the calendar: a US Simponi launch, three FDA approvals expected before year-end, and an Entyvio review all collide in the same window. That raises the binary risk around Q4 and 2027 without changing the underlying scientific position.
The cash clock and the recurring Q4 promise
The balance sheet is the reason the Q4 promise matters so much. Cash ended the quarter at $61 million, down from $143 million at the start. Operations used $89 million, working capital absorbed about $116 million as inventory and supply-chain readiness built ahead of launches, and net borrowings added $82 million including a new loan facility in August. Linda: “Cash on hand at the end of the period was $61 million and $143 million at the beginning of the quarter.” — Linda Jonsdottir, Likely CFO or Head of Finance · 2026-11-12 Interest payments were $37 million in the quarter and are expected to stay around that level until deleveraging begins in the second half of 2027. That is a heavy interest payment burden for a company that is still pre-cash-flow-positive.
This is not a fresh warning—it is a recurring one. On the prior call, management was already pointing to a back-end-loaded year: “we are targeting strong Q4... reaching the guidance like with a strong Q4, but like Q3 will still be impacted from the ramp-up...” — Lisa Graver, Senior Executive, likely Head of Commercial or Strategy (inferred from commercial and strategic discussions) · 2026-08-20. Linda also said then: “Yes. We have good visibility into the next 6 months.” — Linda Jonsdottir, Chief Financial Officer · 2026-03-19 The current call repeats the lower end rather than cutting it, and management still expects Q4 to be cash-flow positive. But the cushion is thinner: a slip in December approvals, a delayed Simponi ruling, or slower partner shipments would force the financing question back to the fore.
The story, then, is not that Alvotech suddenly became a growth company. It is that the manufacturing excuse is finally gone. The FDA has signed off on the process and capacity fixes; the pipeline has first-wave positions in Entyvio and high-dose Eylea; Lotus adds a direct US commercial option; and Lotte/Fujifilm add supply redundancy. The global keyword tape is full of AI data-center and tariff noise; this catalyst is idiosyncratic regulatory execution. What remains is execution against a very concentrated Q4 and a litigation calendar. If the quarter delivers, the de-risking is real and the Lotus model can change the terminal value. If it does not, the conversation reverts to cash, leverage, and another promise of a stronger second half.